Cost-Effectiveness Analysis of Lorlatinib vs Alectinib for ALK-Positive NSCLC in Italy

Ilaria Valentini's 2026 study provides a partitioned survival model evaluating the cost-effectiveness of lorlatinib as first-line treatment for ALK-positive advanced non-small cell lung cancer in Italy. The model uses clinical data from the CROWN trial and network meta-analysis, with costs in 2026 euros and outcomes measured in life-years and quality-adjusted life-years. The base-case analysis found lorlatinib to be dominant, providing higher benefits at lower costs compared to alectinib.

Use Cases

• Validate cost-effectiveness modeling results based on the described partitioned survival model with three health states.
• Compare economic outcomes for ALK inhibitors based on the reported life-year and quality-adjusted life-year gains.
• Assess uncertainty in health economic models based on the described deterministic, probabilistic, and scenario analyses.
• Inform healthcare reimbursement decisions based on the Italian National Health Service and societal perspective findings.

Strengths

• Model is based on clinical efficacy inputs from the CROWN trial and network meta-analysis.
• Analysis includes both Italian National Health Service and societal perspectives over a 30-year horizon.
• Results include specific quantitative outcomes: +2.01 life-years, +1.66 QALYs, and –€19,210 cost savings per patient.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is specific to the Italian healthcare context and a 2026 cost perspective, limiting generalizability.

Provenance

Source

Ilaria Valentini via figshare

Collection Method

Partitioned survival model developed from clinical trial data and economic inputs.

Time Range

Model horizon of 30 years; costs in 2026 euros.

Freshness

Last updated 2026-04-27 16:07:56; freshness should be verified.

Geography

Italy